Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 14/2006

01-10-2006 | Leading Article

Antistaphylococcal Vaccines and Immunoglobulins

Current Status and Future Prospects

Author: Dr Stan Deresinski

Published in: Drugs | Issue 14/2006

Login to get access

Abstract

Staphylococci are among the most frequently encountered pathogens in both the inpatient and the outpatient setting. Management of infections caused by these organisms is complicated by the increasingly common resistance of staphylococcal pathogens to commonly used antibacterials. As a consequence, novel approaches to prevention and treatment are urgently required. Such approaches include the development of vaccines and immunoglobulin preparations targeted at virulence factors expressed in vivo by staphylococci. This article reviews the biopharmaceutical progress made to date in this field and suggests approaches to further progress.
Footnotes
1
The use of trade names is for product identification purposes only and does not imply endorsement.
 
Literature
1.
Laupland KB, Church DL, Mucenski M, et al. Population-based study of the epidemiology of and the risk factors for invasive Staphylococcus aureus infections. J Infect Dis 2003; 187: 1452–9PubMedCrossRef
2.
National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 to June 2004, issued October 2004. Am J Infect Control 2004; 32: 470–85CrossRef
3.
Wisplinghoff H, Bischoff T, Tallent SM. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309–17PubMedCrossRef
4.
Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005; 352: 1436–44PubMedCrossRef
5.
Applebaum PC. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clin Micro-biol Infect 2006; 12 Suppl. 1: 16–23CrossRef
6.
Klingenberg C, Aarag E, Rønnestad A, et al. Coagulase negative staphylococcal sepsis in neonates. Pediatr Infect Dis J 2005; 24: 817–22PubMedCrossRef
7.
Johnson-Robbins LA, el Mohandes AE, Simmens SJ, et al. Staphylococcus epidermidis sepsis in the intensive care nursery: a characterization of risk associations in infants < 1000g. Biol Neonate 1996; 69: 249–56PubMedCrossRef
8.
Etz H, Minh DB, Henics T, et al. Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus. Proc Natl Acad Sci U S A 2002; 99: 6573–8PubMedCrossRef
9.
O’Riordan K, Lee JC. Staphylococcus aureus capsular polysaccharides. Clin Microbiol Rev 2004; 17: 218–34PubMedCrossRef
10.
Roghmann M, Taylor KL, Gupte A, et al. Epidemiology of capsular and surface polysaccharide in Staphylococcus aureus infections complicated by bactaeremia. J Hosp Infect 2005; 59: 27–32PubMedCrossRef
11.
12.
Rivas JM, Speziale P, Patti JM, et al. MSCRAMM-targeted vaccines and immunotherapy for staphylococcal infection. Curr Opin Drug Discov Devel 2004; 7: 223–7PubMed
13.
Josefsson E, Hartford O, O’Brien L, et al. Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant. J Infect Dis 2001; 184: 1572–80PubMedCrossRef
14.
Bloom B, Schelonka R, Kueser T, et al. Mulicenter study to assess safety and efficacy of INH-A21, a donor-selected human staphylococcal immunoglobulin, for prevention of nosocomial infections in very low birth weight infants. Pediatr Infect Dis J 2005; 24: 858–66PubMedCrossRef
15.
Higgins J, Loughman A, van Kessel KP, et al. Clumping factor A of Staphylococcus aureus inhibits phagocytosis by human polymorphonuclear leucocytes. FEMS Microbiol Lett 2006; 258: 290–6PubMedCrossRef
16.
O’Brien LM, Walsh EJ, Massey RC, et al. Staphylococcus aureus clumping factor B (ClfB) promotes adherence to human type I cytokeratin 10: implications for nasal colonization. Cell Microbiol 2002; 4: 759–70PubMedCrossRef
17.
Xu Y, Rivas JM, Brown EL, et al. Virulence potential of the staphylococcal adhesin CNA in experimental arthritis is determined by its affinity for collagen. J Infect Dis 2004; 189: 2323–33PubMedCrossRef
18.
Endl J, Seidl HP, Fiedler F, et al. Chemical composition and structure of cell wall teichoic acids of staphylococci. Arch Microbiol 1983; 135: 215–23PubMedCrossRef
19.
Garcia-Lara J, Masalha M, Foster SJ. Staphylococcus aureus: the search for novel targets. Drug Discov Today 2005; 10: 643–51PubMedCrossRef
20.
Wiedenmaier C, Kokai-Kun JF, Kristian SA, et al. Role of teichoic acids in Staphylococcus aureus nasal colonization, a major risk factor in nosocomial infections. Nat Med 2004; 10: 243–5CrossRef
21.
Weidenmaier C, Peschel A, Xiong YQ, et al. Lack of wall teichoic acids in Staphylococcus aureus leads to reduced interactions with endothelial cells and to attenuated virulence in a rabbit model of endocarditis. J Infect Dis 2005; 191: 1771–7PubMedCrossRef
22.
23.
Davidson AL, Chen J. ATP-binding cassette transporters in bacteria. Annu Rev Biochem 2004; 73: 241–68PubMedCrossRef
24.
25.
Kuroda M, Ohta T, Uchiyama I, et al. Whole genome sequencing of methicillin-resistant Staphylococcus aureus. Lancet 2001; 357: 1225–40PubMedCrossRef
26.
Miethke T, Duschek K, Wahl C, et al. Pathogenesis of the toxic shock syndrome: T cell mediated lethal shock caused by the superantigen TSST-1. Eur J Immunol 1993; 23: 1494–500PubMedCrossRef
27.
Kaneko J, Kamio Y. Bacterial two-component and hetero-heptameric pore-forming cytolytic toxins: structures, pore-forming mechanism, and organization of the genes. Biosci Biotechnol Biochem 2004; 68: 981–1003PubMedCrossRef
28.
Gillet Y, Issartel B, Vanhems P, et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotizing pneumonia in young immunocompetent patients. Lancet 2002; 359: 753–9PubMedCrossRef
29.
Fattom A, Schneerson R, Szu SC, et al. Synthesis and immunologic properties in mice of vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides conjugated to Pseudomonas aeruginosa exotoxin A. Infect Immun 1990; 58: 2367–74PubMed
30.
Fattom A, Schneerson R, Watson DC, et al. Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A. Infect Immun 1993; 61: 1023–32PubMed
31.
Fattom A, Li X, Cho YH, et al. Effect of conjugation methodology, carrier protein, and adjuvants on the immune response to Staphylococcus aureus capsular polysaccharides. Vaccine 1995; 13: 1288–93PubMedCrossRef
32.
Welch PG, Fattom A, Moore J, et al. Safety and immunogenicity of Staphylococcus aureus type 5 polysaccharide-Pseudomonas aeruginosa recombinant exoprotein A conjugate vaccine in patients on hemodialysis. J Am Soc Nephrol 1996; 7: 247–53PubMed
33.
Shinefield H, Black S, Fattom A, et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med 2002; 346: 491–6PubMedCrossRef
34.
35.
36.
37.
38.
39.
40.
Benjamin DK, Schelonka R, White R, et al. A blinded, randomized, multicenter study of an intravenous Staphylococcus aureus immune globulin. J Perinatol 2006; 26: 290–5PubMedCrossRef
41.
Mandy GT, Weisman LE, Horwith G, et al. Safety of Staphylococcus aureus intravenous human immune globulin (Alta Staph) in very-low-birth-weight neonates [abstract no. 2023]. 2000 Pediatric Academic Societies’ Annual Meeting; May 12–16; Boston [online]. Available from URL: http://​www.​pas-meeting.​org/​ [Accessed 2006 Sep 3]
42.
Rupp ME, Lutz J, Dicpingaitis P, et al. Trial of Staphylococcus aureus capsular polysaccharide immune globulin in subjects with S. aureus bacteremia and persistent fever [abstract no. LB-14]. 43rd Meeting of the Infectious Disease Society of America; 2005 Oct 6–9; San Francisco
43.
Vernachio J, Bayer AS, Le T, et al. Anti-clumping factor A immunoglobulin reduces the duration of methicillin-resistant Staphylococcus aureus bacteremia in an experimental model of infective endocarditis. Antimicrob Agents Chemother 2003; 47: 3400–6PubMedCrossRef
44.
Vernachio JH, Bayer AS, Ames B, et al. Human immunoglobulin G recognizing fibrinogen-binding surface proteins is protective against both Staphylococcus aureus and Staphylococcus epidermidis infections in vivo. Antimicrob Agents Chemother 2006; 50: 511–8PubMedCrossRef
45.
Kaufman D. Veronate Inhibitex. Curr Opin Invest Drugs 2006; 7: 172–9
46.
Capparelli EV, Bloom BT, Kueser TJ, et al. Multicenter study to determine antibody concentrations and assess the safety of administration of INH-A21, a donor-selected human Staphylococcal immune globulin, in low-birth weight infants. Antimicrob Agents Chemother 2005; 49: 4121–7PubMedCrossRef
47.
De Jonge M, Burchfield D, Bloom B, et al. A phase III clinical trial of Veronate for prevention of staphylococcal sepsis in premature infants [poster no. 2857.187]. 2006 Pediatric Academic Societies’ Annual Meeting; 2006 Apr 28–May 1; Baltimore (MD)
48.
Hall AE, Domanski PJ, Patel PR, et al. Characterization of a protective monoclonal antibody recognizing Staphylococcus aureus. Infect Immun 2003; 71: 6864–70PubMedCrossRef
49.
Reilley S, Wenzel E, Reynolds L, et al. Open-label, dose escalation study of the safety and pharmacokinetic profile of tefibazumab in healthy volunteers. Antimicrob Agents Chemother 2005; 49: 959–62PubMedCrossRef
50.
Domanski PJ, Patel PR, Bayer AS, et al. Characterization of a humanized monoclonal antibody recognizing clumping factor A expressed by Staphylococcus aureus. Infect Immun 2005; 73: 5229–32PubMedCrossRef
51.
Patti JM. A humanized monoclonal antibody targeting Staphylococcus aureus. Vaccine 2004; 22 Suppl. 1: S39–43PubMedCrossRef
52.
Weems J Jr, Steinberg JP, Filler S, et al. Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2006; 50: 2751–5PubMedCrossRef
53.
54.
Burnie JP, Matthews RC, Carter T, et al. Identification of an immunodominant ABC transporter in methicillin-resistant Staphylococcus aureus infections. Infect Immun 2000; 68: 3200–9PubMedCrossRef
55.
56.
Weisman LE, Schuman RF, Lukomska E, at al. Effectiveness and pharmacokinetics of an anti-lipoteichoic acid humanized mouse chimeric monoclonal antibody. 2001 Pediatric Academic Societies’ Annual Meeting; 2001 Apr 28-May 1; Baltimore (MD)
57.
58.
Weisman LE, Fischer GW, Mandy GT, et al. Safety and pharmacokinetics of an anti-lipoteichoic acid humanized mouse chimeric monoclonal antibody in healthy adults [abstract no. 1572]. 2002 Pediatric Academic Societies’ Annual Meeting; 2002 May 4–7; Baltimore (MD)
59.
Weisman LE, Mandy GT, Garcia-Prats JA, et al. Safety and pharmacokinetics of an anti-lipoteichoic acid humanized mouse chimeric monoclonal antibody for prevention of coagulase negative staphylococcal infection in very low birth weight infants: preliminary report [abstract no. 1800]. 2003 Pediatric Academic Societies’ Annual Meeting; 2003 May 3–6; Seattle (WA)
60.
Thackray H, Lassiter H, Walsh W, et al. Phase II randomized, double-blind, placebo-controlled, safety, pharmacokinetics, and clinical activity study in very low birth weight neonates of pagibaximab, a monoclonal antibody for the prevention of staphylococcal infection [abstract no. 3724.6]. 2006 Pediatric Academic Societies’ Annual Meeting; 2006 Apr 29–May 2; San Francisco (CA)
61.
Schroder A, Kland R, Peschel A, et al. Live cell imaging of phagosome maturation in Staphylococcus aureus infected human endothelial cells: small colony variants are able to survive in lysosomes. Med Microbiol Immunol. Epub 2006 Apr 5
62.
Proctor RA, von Eiff C, Kahl BC, et al. Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections. Nat Rev Microbiol 2006; 4: 295–305PubMedCrossRef
63.
Mack D, Becker P, Chatterjee I, et al. Mechanisms of biofilm formation in Staphylococcus epidermidis and Staphylococcus aureus functional molecules, regulatory circuits, and adaptive responses. Int J Med Microbiol 2004; 294: 203–12PubMedCrossRef
64.
65.
Nour El-Din AN, Shkreta L, Talbot BG, et al. DNA immunization of dairy cows with the clumping factor A of Staphylococcus aureus. Vaccine 2006; 24: 1997–2006PubMedCrossRef
66.
Shkreta L, Talbot BG, Diarra MS, et al. Immune responses to a DNA/protein vaccination strategy against Staphylococcus aureus induced mastitis in dairy cows. Vaccine 2004; 23: 114–26PubMedCrossRef
67.
Schaffer AC, Solinga RM, Cocchiaro J, et al. Immunization with Staphylococcus aureus clumping factor B, a major determinant in nasal carriage, reduces nasal colonization in a murine model. Infect Immun 2006; 74: 2145–53PubMedCrossRef
68.
Nilsson IM, Patti JM, Bremell T, et al. Vaccination with a recombinant fragment of collagen adhesin provides protection against Staphylococcus aureus-mediated septic death. J Clin Invest 1998; 101: 2640–9PubMedCrossRef
69.
Zhou H, Xiong ZY, Li HP, et al. An immunogenicity study of a newly fusion protein Can-FnBP vaccinated against Staphylococcus aureus in a mice model. Vaccine. Epub 2006 Mar 24
70.
Hu DL, Omoe K, Sasaki S, et al. Vaccination with nontoxic mutant toxic shock syndrome toxin 1 protects against Staphylococcus aureus infection. J Infect Dis 2003; 188: 743–52PubMedCrossRef
71.
Cui JC, Hu DL, Lin YC, et al. Immunization with glutathione S-transferase and mutant toxic shock syndrome toxin 1 fusion protein protects against Staphylococcus aureus infection. FEMS Immunol Med Microbiol 2005; 45: 45–51PubMedCrossRef
72.
Andrews MM, Parent EM, Barry M, et al. Recurrent nonmen-strual toxic shock syndrome: clinical manifestations, diagnosis, and treatment. Clin Infect Dis 2001; 32: 1470–9PubMedCrossRef
73.
Darenberg J, Soderquist B, Henriques Normark B, et al. Differences in potency of intravenous polyspecific immunoglobulin G against streptococcal and staphylococcal superantigens: implications for therapy of toxic shock syndrome. Clin Infect Dis 2004; 38: 836–42PubMedCrossRef
74.
Gauduchon V, Cozon G, Vandenesch F, et al. Neutralization of Staphylococcus aureus Panton Valentine leukocidin by intravenous immunoglobulin in vivo. Clin Infect Dis 2004; 189: 346–53
75.
Robbins JB, Schneerson R, Horwith G, et al. Staphylococcus aureus types 5 and 8 capsular polysaccharide-protein conjugate vaccines. Am Heart J 2004; 147: 593–8PubMedCrossRef
76.
77.
Metadata
Title
Antistaphylococcal Vaccines and Immunoglobulins
Current Status and Future Prospects
Author
Dr Stan Deresinski
Publication date
01-10-2006
Publisher
Springer International Publishing
Published in
Drugs / Issue 14/2006
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200666140-00002

Other articles of this Issue 14/2006

Drugs 14/2006 Go to the issue

Guest Commentary

Pioglitazone/Metformin

Guest Commentary

Pioglitazone/Metformin

Adis Drug Evaluation

Valsartan/Hydrochlorothiazide

Current Opinion

Remission, a Therapeutic Goal in Inflammatory Arthropathies?

Adis Drug Profile

Pioglitazone/Metformin

Review Article

Natural Course, Therapeutic Options and Economic Evaluation of Therapies for Chronic Hepatitis B